Business Context and Reporting Period
This Form 8-K Current Report was filed by IDEAYA Biosciences, Inc. on February 17, 2021, regarding events occurring on February 12, 2021. The filing discloses the appointment of a new member to the Company's Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance changes.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- New Appointment: Susan L. Kelley, M.D., was appointed as a Class III director, effective February 12, 2021. Her initial term expires at the 2022 annual meeting of stockholders.
- Independence: The Company determined Dr. Kelley qualifies as an "independent director" under Nasdaq listing standards.
Compensation and Governance Details
- Equity Grant: Dr. Kelley received an option to purchase 22,000 shares of common stock. The exercise price equals the closing price on February 12, 2021.
- Vesting Schedule: The option vests monthly at a rate of 1/36th of the shares subject to the option, contingent on continued service.
- Committee Assignments: Dr. Kelley has not been named to any Board committees at this time.
- Indemnification: A standard director and officer indemnification agreement was executed.
Investor Verification Checklist
- Verify the closing stock price on February 12, 2021, to determine the exercise price of the 22,000 share option granted to Dr. Kelley.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 27, 2021) for details on the non-employee director compensation program.
- Confirm the total number of outstanding shares and the dilution impact of the new option grant.
- Monitor future filings for Dr. Kelley's assignment to specific Board committees.